Role of nitric oxide in cancer biology

Free Radical Research

Volumn 31, Issue 6, 1999, Pages 671-679

  Moochhala, Shabbir ^a   Rajnakova, Andrea ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Cyclooxygenase; Nitric oxide; p53; Tumor

Indexed keywords

DNA; NITRIC OXIDE; PROSTAGLANDIN SYNTHASE;

CARCINOGENESIS; CONFERENCE PAPER; DNA DAMAGE; HUMAN; IMMUNE DEFICIENCY; NONHUMAN; TRANSCRIPTION REGULATION; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0032740246     PISSN: 10715762     EISSN: None     Source Type: Journal    
DOI: 10.1080/10715769900301231A     Document Type: Conference Paper

References (86)

1. S. Moncada, R.M.J. Palmer and E.A. Higgs, Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacological Reviews 1991; 43: 109-141.
2. D.J. Stuehr and M.A. Marietta, Mammalian nitrite biosynthesis: Mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proceedings of the National Academy of Science of the United States of America 1985; 82: 7738-7742.
3. D.E. Koshland Jr., The molecule of the year. Science 1992; 258: 1861.
4. Y. Henry, M. Lepoivre, J.C. Drapier, C. Ducrocq, J.L. Boucher and A. Guissani, ERP characterization of molecular targets of NO in mammalian cells and organelles. FASEB Journal 1993; 7: 1124-1134.
5. J.S. Stamler, D.J. Singel and J. Loscalzo, Biochemistry of nitric oxide and its redox activated forms. Science 1992; 258: 1898-1902.
6. J.M. Fukuto, Chemistry of nitric oxide: Biologically relevant aspects. In: Ignarro, L. and Murad, F. (Eds.) Nitric oxide - biochemistry, molecular biology and therapeutic implications. Advances in Pharmacology. Academic Press, USA 1995; pp. 1-15.
7. L.J. Ignarro, Heme-dependent activation of cytosolic guanylate cyclase by nitric oxide: A widespread signal transduction mechanism. Biochemical Society Transactions 1992; 20: 465-469.
8. L.J. Ignarro, Heme-dependent activation of soluble guanylate cyclase by nitric oxide: Regulation of enzyme activity by porphyrins and metallophorphyrins. Seminars in Hematology 1989; 26: 63-76.
9. R. Radi, J.S. Beckman, K.M. Bush and B.A. Freeman, Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide. Archives of Biochemistry and Biophysics 1991; 288: 481-487.
10. D.A. Wink, Y. Vodovotz, J. Laval, F. Laval, M.W. Dewhirst and J.B. Mitchell, The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998; 19: 711-721.
11. D.A. Wink, J.A. Cook, S. Kim,Y. Vodovotz, R. Pacelli, M.C. Krishna, A. Russo, J.B. Mitchell, D. Jourd'heuil, A.M. Miles and M.B. Grisham, Superoxide modulates the oxidation and nitrosation of thiol by nitric oxide derived reactive intermediates. Journal of Biological Chemistry 1997; 272: 1147-11512.
12. P. Correa, C. Cuello, L.F. Fajardo, W. Haenszel, O. Bolanos and B. de Ramirez, Diet and gastric cancer: Nutrition survey in a high-risk area. Journal of the National Cancer Institute 1983; 70: 673-678.
13. H. Marquardt, F. Rufino and J.H. Weisburger, Mutagenic activity of nitrite-treated foods: Human stomach cancer may be related to dietary factors. Science 1977; 196: 1000-1001.
14. H.W. Taylor and W. Lijinski, Tumor induction in rats by feeding heptamethyleneimine and nitrite in water. Cancer Research 1975; 35: 812-815.
15. C.L. Lintas, A. Clark, J. Fox, S.R. Tannenbaum and P.M. Newberne, In view stability of nitrite and nitrosamine formation in the dog stomach: Effect of nitrite and amine concentration and of ascorbic acid. Carcinogenesis 1982; 3: 161-165.
16. J.H. Weisburger, H. Marquardt, N. Hirota, H. Mori and G.M. Williams, Induction of cancer of the glandular stomach in rats by an extract of nitrite-treated fish. Journal of the National Cancer Institute 1980; 64: 163-167.
17. S.S. Mirvish, S. Salmasi, S.M. Cohen, K. Patil and E. Mahboubi, Liver and forestomach tumors and other forestomach lesions in rats treated with morpholine and sodium nitrite, with and without sodium ascorbate. Journal of the National Cancer Institute 1983; 71: 81-85.
18. D.A. Wink, I. Hanbauer, M.B. Grisham, F. Laval, R.W. Minis, J. Laval, J.C. Cook, R. Pacelli, J. Liebmann, M.C. Krishna, M.C. Ford and J.B. Mitchell, The chemical biology of NO. Insights into regulation, protective and toxic mechanisms of nitric oxide. Current Topics in Cellular Regulation 1996; 34: 159-187.
19. M.A. Marietta, Mammalian synthesis of nitrite, nitrate, nitric oxide, and N-nitrosating agents. Chemical Research in Toxicology 1988; 1: 249-257.
20. A.M. Miles, M. Gibson, M. Krishna, J.C. Cook, R. Pacelli, D.A. Wink and M.B. Grisham, Effects of superoxide on nitric oxide-dependent N-nitrosation reactions. Free Radical Research 1995; 233: 379-390.
21. R.H. Liu and J.H. Hotchkiss, Potential genotoxicity of chronically elevated nitric oxide: A review. Mutation Research 1995; 339: 73-89.
22. H. Ohshima and H. Bartsch, Chronic infections and inflammatory processes as cancer risk factors: Possible role of nitric oxide in carcinogenesis. Mutation Research 1994; 305: 253-264.
23. D.A. Wink, K.S. Kasprzak, C.M. Maragos, R.K. Elespuru, M. Misra, T.M. Dunams, T.A. Cebula, W.H. Koch, A.W. Andrews, J.S. Allen and L.K. Keefer, DNA deaminating ability and genotoxicity of nitric oxide and its progenitors. Science 1991; 254: 1001-1003.
24. T. Nguyen, D. Brunson, C.L. Crespi, B.W. Penman, J.S. Wishnok and S.R. Tannenbaum, DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proceedings of the National Academy of Sciences of the United States of America 1992; 89: 3030-3034.
25. K. Merchant, H. Chen, T.C. Gonzales, L.K. Keefer and B.R. Shaw, Deamination of single-stranded DNA cytosine residues in aerobic nitric oxide solution at micromolar total NO exposures. Chemical Research in Toxicoloqy 1996; 9: 891-896.
26. T. DeRojas-Walker, S. Tamir, H. Ji, J.S. Wishnok and S.R. Tannenbaum, Nitric oxide induces oxidative damage in addition to deamination in macrophage DNA. Chemical Research in Toxicology 1995; 8: 473-477.
27. M.G. Salgo, K. Stone, G.L. Squadrito, J.R. Battista and W.A. Pryor, Peroxynitrite causes DNA nicks in plasmid pBR322. Biochemical and Biophysical Research Communications 1995; 210: 1025-1030.
28. 6-methylguanine-DNA-methyltransferase activity: Analysis of three residues at or near the methyl acceptor site. Carcinogenesis 1992; 13: 837-843.
29. 6-methylguanine-DNA-methyltransferase. Journal of Biological Chemistry 1994; 269: 730-733.
30. 2 reaction. Chemical Research in Toxicology 1994; 7: 519-525.
31. D. Rhodes and A. Klug, Zinc fingers. Scientific American 1993; 268: 56-65.
32. D.A. Wink and J. Laval, The Fpg protein, a DNA repair enzyme, is inhibited by the biomediator nitric oxide in vitro and in vivo. Carcinogenesis, 1994; 15: 2125-2129.
33. U.K. Messmer, M. Ankarcrona, P. Nicotera and B. Brune, P53 expression in nitric oxide-induced apoptosis. FEBS Letters 1994; 355: 23-26.
34. L.L. Thomsen, D.W. Miles, L. Happerfield, L.G. Bobrow, R.G. Knowles and S. Moncada, Nitric oxide synthase activity in human breast cancer. British Journal of Cancer 1995; 72: 41-44.
35. L.L. Thomsen, F.G. Lawton, R.G. Knowles, J.E. Beesley, V. Riveros-Moreno and S. Moncada, Nitric oxide synthase activity in human gynecological cancer. Cancer Research 1994; 54: 1352-1354.
36. C.S. Cobbs, J.E. Brenman, K.D. Aldape, D.S. Bredt and M.A. Israel, Expression of nitric oxide synthase in human central nervous system tumors. Cancer Research 1995; 55: 727-730.
37. W. Radomski, D.C. Jenkins, L. Holmes and S. Moncada, Human colorectal adenocarcinoma cells: Differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Research 1991; 51: 6073-6078.
38. J. Prazma, P. Petrusz, W. Mims, S.S. Ball and M.C. Weissler, Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. Otolaryngology and Head and Neck Surgery 1995; 13: 541-549.
39. J. Folkman, Angiogenesis and angiogenesis inhibition: An overview. EXS 1997; 79: 1-8.
40. N. Weidner, J.P. Semple, W.R. Welch and J. Folkman, Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. New England Journal of Medicine 1991; 324: 1-8.
41. S. Ambs, W.P. Bennett, W.G. Merriam, M.O. Ogunfusika, S.M. Oser, A.M. Harrington, P.G. Shields, E. Felley-Bosco, S.P. Hussain and C.C. Harris, Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. Journal of the National Cancer Institute 1999; 91: 86-88.
42. S.M. Moochhala, V.J.S. Chhatwall, S.T.F. Chan, S.S. Ngoi, Y.W. Chia and A. Rauff, Nitric oxide synthase activity and expression in human colorectal cancer. Carcinogenesis 1996; 17: 1171-1174.
43. R.M. Sutherland, J.S. Rasey and R.P. Hill, Tumor biology. American Journal of Clinical Oncology 1988; 11: 253-274.
44. E. Pipili-Synetos, A. Papageorgiou, E. Sakkoula, G. Sotiropoulou, G. Fotsis, G. Karakiulakis and M. Maragoudakis, Inhibition of angiogenesis, tumor growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. British Journal of Pharmacology 1995; 116: 1829-1834.
45. J.G. De Man, P.A. Pelckmans, G.E. Boeckxstaens, H. Bult, L. Oosterbosch, O. Hatjikondi, P. Ravazoula, D. Kardamakis, J. Dimopoulos and S. Papaioannou, In vivo experimental evidence that the nitric oxide pathway is involved in the X-ray-induced antiangiogenicity. British Journal of Cancer 1996; 74: 1916-1923.
46. M. Ziehe, L. Morbidelli, E. Masini, S. Amerini, H.J. Granger, C.A. Maggi, P. Geppetti and F. Ledda, Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. Journal of Clinical Investigation 1994; 94: 2036-2044.
47. D.C. Jenkins, I.G. Charles, L.L. Thomsen, D.W. Moss, L.S. Holmes, S.A. Baylis, P. Rhodes, K. Westmore, P.C. Emson and S. Moncada, Roles of nitric oxide in tumor growth. Proceedings of the National Academy of Sciences of the United States of America 1995; 92: 4392-4396.
48. M. Lepoivre, B. Chenais, A. Yapo, G. Lemaire, L. Thelander and J.P. Tenu, Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells. Journal of Biological Chemistry1990; 265: 14 143-14 149.
49. M. Lepoivre, F. Fieschi, J. Coves, L. Thelander and M. Fontecave, Inactivation of ribonucleotide reductase by nitric oxide. Biochemical and Biophysical Research Communications 1991 ; 179: 442-448.
50. M. Lepoivre, J.M. Flaman and Y. Henry, Early loss of the tyrosyl radical in ribonucleotide reductase of adenocarcinoma cells producing nitric oxide. Journal of Biological Chemistry 1992; 267: 22 994-23 000.
51. J.R. Lancaster and I.B. Hibbs, EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages. Proceedings of the National Academy of Sciences of the United States of America 1990; 87: 1223-1227.
52. J.C. Drapiers, H. Hiding, J. Wietzerbin, P. Kaildy and L.C. Kuhn, Biosynthesis of nitric oxide activates iron regulatory factor in macrophages. EMBO Journal 1993; 12: 3643-3649.
53. G. Weiss, B. Goossen, W. Doppler, K. Pantopoulos, G. Werner-Felmayer and M.W. Hentze, Translational regulation via iron-responsive elements by the nitric oxide/NO synthase pathway. EMBO Journal 1993; 12: 3651-3657.
54. C. Bouton, M. Raveau and J.C. Drapier, Modulation of iron regulatory protein function. Further roles of nitrogen and oxygen-derived reactive species. Journal of Biological Chemistry 1996; 271: 2300-2306.
55. M. Graziewicz, D.A. Wink and F. Laval, Nitric oxide inhibits DNA ligase activity. Potential mechanism for NO mediated DNA damage. Carcinogenesis 1996; 17: 2501-2505.
56. R. Radi, J.S. Beckman, K.M. Bush and B.A. Freeman, Peroxynitrate oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. Journal of Biological Chemistry 1991; 266: 4244-4250.
57. J.P. Spencer, J. Wong, A. Jenner, O.I. Aruoma, C.E. Cross and B. Halliwell, Base modification and strand breakage in isolated calf thymus DNA and in DNA from human skin epidermal keratinocytes exposed to peroxynitrite or 3-morpholinosydnonimine. Chemical Research in Toxicology 1996; 9: 1152-1158.
58. H. Ohshima, Y. Yoshie, S. Auriol and I. Gilibert, Antioxidant and pro-oxidant actions of flavonoids: Effects on DNA damage induced by nitric oxide, peroxynitrite and nitroxyl anion. Free radical Biology and Medicine 1998; 25: 1057-1065.
59. K. Forrester, S. Ambs, S.E. Lupold, R.B. Kapust, E.A. Spillare, W.C. Weinberg, E. Felley-Bosco, X.W. Wang, D.A. Geller, E. Tzeng, T.R. Billiar and C.C. Harris, Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 2442-2447.
60. S.J. Baker, S. Markowitz, E.R. Fearon, J.K.V. Willson and B. Vogelstein, Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249: 912-915.
61. M.B. Kastan, O. Onykewere, D. Sidransky, B. Vogelstein and R. W. Craig, Participation of p53 protein in the cellular response to DNA damage. Cancer Research 1991; 51: 6304-6311.
62. S. Tsuji, M. Tsujii, W.H. Sun, E.S. Gunawan, H. Murata, S. Kawano and M. Hori, Helicobacter pylori and gastric carcinogenesis. Journal of Clinical Gastroenterology 1997; 25: S186-S197.
63. K.M. Dameron, O.V. Volpert, M.A. Tainsky and N. Bouck, Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265: 1582-1584.
64. T.G. Graeber, C. Osmanian, T. Jacks, D.E. Housman, C.J. Koch, S.W. Lowe and A.J. Giaccia, Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature (Loud.) 1996; 379: 88-91.
65. S. Ambs, W.G. Merriam, M.O. Ogunfusika, W.P. Bennett, N. Ishibe, S.P. Hussain, E.E. Tzeng, D.A. Geller, T.R. Billiar and C.C. Harris, P53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nature Medicine 1998; 4: 1371-1376.
66. G. Melillo et al., A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. Journal of Experimental Medicine 1995; 182: 1683-1693.
67. G. Montrucchio, E. Lupia, A. de Martino, E. Battaglia, M. Arese, A.S. Tizzani, F. Bussolino and G. Camussi, Nitric oxide mediates angiogenesis induced in vivo by platelet-activating factor and tumor necrosis factor-α. American Journal of Pathology 1997; 151: 557-563.
68. N.Z. Wu, B. Klitzman, R. Dodge and M.W. Dewhirst, Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Research 1992; 52: 4265-4268.
69. B.V. Khan, D.G. Harrison, MT. Olbrych, R.W. Alexander and R.M. Medford, Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 9114-9119.
70. S. Nakano, K. Matsukado and K.L. Black, Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Research 1996; 56: 4027-4031.
71. A. Orucevic and P.K. Lala, Effects of N(g)-methyl-L-arginine, an inhibitor of nitric oxide synthesis, on interleukin-2-induced capillary leakage and antitumor responses in healthy and tumor-bearing mice. Cancer Immunology, Immunotheraphy 1996; 42: 38-46.
72. C.S. Parkins, M.F. Dennis, M.R. Stratford, S.A. Hill and D.J. Chaplin, Ischemia reperfusion injury in tumors: The role of oxygen radicals and nitric oxide. Cancer Research 1995; 55: 6026-6029.
73. P. Lejeune, C.P. Lagade, N. Onier, D. Pinard, H. Ohshima and J.F. Jeannin, Nitric oxide involvement in tumor-induced immunosuppression. Journal of Immunology 1994; 152: 5077-5083.
74. C.D. Mills, Molecular basis of 'supressor' macrophages. Arginine metabolism via the nitric oxide synthetase pathway. Journal of Immunology 1991; 146: 2714-2723.
75. N.E. Hubbard and K.L. Erickson, Role of 5-lipoxygenase metabolites in the activation of peritoneal macrophages for tumoricidal function. Cellular Immunology 1995; 160: 115-122.
76. D. Salvemini, T.P. Misko, J.L. Masferrer, K. Seibert, M.G. Currie and P. Needleman, Nitric oxide activates cyclooxygeenase enzymes. Proceeding of the National Academy of Sciences of the United States of America 1993; 90: 7420-7444.
77. T.E. Gardner, H. Naama and J.M. Daly, Peritoneal and splenic macrophage functions in the tumor-bearing host. Journal of Surgical Research 1995; 59: 305-310.
78. H. Maeda, Y. Noguchi, K. Sato and T. Akaike, Enhanced vascular permeability in solid tumor is mediated by nitric-oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Japanese Journal of Cancer Research 1994; 85: 331-334.
79. M. Tsujii and R.N. DuBois, Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
80. H. Sawaoka, S. Tsuji, M. Tsujii, E.S. Gunawan, A. Nakama, Y. Takei, K. Nagano, H. Matsui, S. Kawano and M. Hori, Expression of the cyclooxygenase-2 gene in gastric epithelium. Clinical gastroenterology 1997; 25: S105-S110.
81. L.L. Thomson, D.W. Miles, L. Happerfield, L.G. Bobrow, R.G. Knowles and S. Moncada, Nitric oxide synthase activity in human breast cancer. British Journal of Cancer 1995; 72: 41-44.
82. E. Ellie, H. Loiseau, F. Lafond, J. Arsaut and J. Demotes-Mainard, Differential expression of inducible nitric oxide synthase mRNA in human brain tumors. Neuroreport 1995; 7: 294-296.
83. S. Cascinu, F. Graziano, E. Del Ferro, M.P Staccioli, M. Ligi, A. Carnevali, P. Muretto and G. Catalano, Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma. Cancer 1998; 83: 1917-1922.
84. B.V. Joypaul, D. Hopwood, E.L. Newman, S. Qureshi, A. Grant, S.A. Ogston et al., The prognostic significance of the accumulation of p53 tumor suppressor gene protein in gastric adenocarcinoma. British Journal of Cancer 1994; 69: 943-946.
85. H.E. Gabbert, W. Muller, A. Schneiders, S. Meier and G. Hommel, The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer 1995; 76: 720-726.
86. M. Victorzon, S. Nordling, C. Haglund, J. Lundin and P.J. Roberts, Expression of p53 protein as a prognostic factor in patients with gastric cancer. European Journal of Cancer 1996; 32A: 215-220.